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OBJECTIVES The expression of endothelial adhesion molecules and their functional significance in
leukocyte adhesion to human myocardial blood vessels in acute myocardial infarction (AMI)
were studied.
BACKGROUND Leukocyte extravasation, mediated by specific adhesion molecules, exacerbates tissue injury
after restoration of blood supply to an ischemic tissue. Experimental myocardial reperfusion
injury can be alleviated with antibodies that block the function of adhesion molecules involved
in leukocyte emigration, but the relevant molecules remain poorly characterized in human
AMI.
METHODS Semiquantitative immunohistochemistry and in vitro adhesion assays were used to study the
expression and granulocyte binding abilities of different endothelial adhesion molecules in
human AMI. Changes in the molecular nature of vascular adhesion protein-1 (VAP-1) were
evaluated using immunoblotting.
RESULTS Certain endothelial adhesion molecules (intercellular adhesion molecule [ICAM-2], CD31
and CD73) were expressed in myocardial blood vessels homogeneously in normal and
ischemic hearts, whereas others (E-selectin and peripheral lymph node addressin) were
completely absent from all specimens. The synthesis of ICAM-1 was locally, and that of
P-selectin regionally, upregulated in the infarcted hearts when compared with nonischemic
controls. Vascular adhesion protein-1 showed ventricular preponderance in expression and
alterations in posttranslational modifications during ischemia-reperfusion. Importantly,
P-selectin, ICAM-1 and VAP-1 mediated granulocyte binding to blood vessels in the
ischemic human heart.
CONCLUSIONS Human P-selectin, ICAM-1 and VAP-1 appear to be the most promising targets when
antiadhesive interventions preventing leukocyte-mediated tissue destruction after myocardial
ischemia are planned. (J Am Coll Cardiol 2000;36:122–9) © 2000 by the American College
of Cardiology
Inappropriate inflammatory responses can cause severe tis-
sue destruction. During ischemia-reperfusion, such as in
acute myocardial infarction (AMI), the tissue damage may
result not only from direct anoxic and hypoxic injury but
also from other deleterious events occurring after the re-
establishment of blood flow to the occluded vascular bed.
The reperfusion injury is partly caused by oxygen radicals,
proteolytic enzymes and cytokines released by adhered and
activated leukocytes that infiltrate into the affected area
(1,2), because neutrophil depletion or prevention of neutro-
phil accumulation significantly diminishes tissue damage
and enhances the recovery of cardiac function (3–8).
Leukocytes gain entrance into the myocardium by bind-
ing to and passing through the endothelial layer of blood
vessels. Multiple homing-associated leukocyte receptors in-
teract in a concerted manner with vascular adhesion ligands
during the process of extravasation (9,10). On endothelium,
selectin-type adhesion molecules (E-selectin [CD62E] and
P-selectin [CD62P]) can bind leukocytes under conditions
of flow and mediate the initial tethering and rolling events.
After activation of the leukocyte, other endothelial mole-
cules such as intercellular adhesion molecule-1 (ICAM-1,
CD54) and ICAM-2 (CD102) and vascular cell adhesion
molecule-1 (VCAM-1, CD106) and CD31 are brought
into play. These molecules allow stable adherence of the
leukocyte and the subsequent extravasation between endo-
thelial cells. Still other endothelial adhesion molecules, like
vascular adhesion protein-1 (VAP-1) (11) and CD73 (12)
are also involved in leukocyte-endothelial cell interactions.
An upregulation of adhesion molecules in myocardial
ischemia and reperfusion in animal models has been re-
ported (13–15). The success of reducing injury during
reperfusion by anti-adhesive therapy in animals raises hopes
for analogous intervention strategies in humans. An adhe-
sion molecule that is absent from the normal myocardium
but is induced after ischemia would be an ideal target for
therapy. Here we analyzed the expression and granulocyte-
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binding function of several endothelial adhesion molecules
(EAMs) in normal and infarcted cardiac specimens in man.
METHODS
Cardiac specimens. The ischemia-reperfusion material
consists of 10 patients who died in the coronary care unit of
Turku University Central Hospital due to AMI (Table 1).
At autopsy, samples across the entire thickness of the
ventricular wall were taken from the macroscopically in-
farcted area, remote left ventricle, borderzone between the
infarcted area and the remote myocardium and from the
ischemia-reperfusion area. Reperfusion specimens were ob-
tained from six thrombolyzed patients (with rapidly resolv-
ing ST changes and resolution of the chest pain [16]) from
the area supplied by a patent infarct-related artery.
Autopsy samples of nonischemic ventricles (8) and atria
(3) were from patients who died of non-AMI causes. We
also studied right atrial samples obtained from 12 patients
undergoing heart surgery. All these tissues were macroscop-
ically normal.
The mean age in the control group was 55 years and in
the infarcted group 63 years. In the control group 3/8 and in
the infarcted group 2/10 were women. To ensure optimal
quality of these autopsy samples, special arrangements were
made to shorten the time between death and autopsy to
,48 h whenever possible (mean 2.4 days).
Human tonsil tissue was used as a positive control and as
a standard for staining intensity in each experiment. In
studies controlling possible effects of postmortem autolysis
with tonsils intentionally exposed for autolysis for 0 to 8
days, hilar lymph nodes from cadavers stored up to six days
and surgical samples from papillary muscle, we did not see
any significant changes in the ability of our antibodies to
react with EAMs. The only exception was VCAM-1, which
in the tonsil showed slight but progressive decrease. All
procedures for tissue collection were approved by the Na-
tional Board of Medicolegal Affairs in Finland.
Antibodies and immunohistochemical stainings. Mouse
monoclonal antibodies (mAbs) against human CD31 (2C8,
IgM), CD73 (4G4, IgG1), ICAM-1 (5C3, IgG1),
ICAM-2 (CBR-1C2/2, IgG2a), E-selectin (P2H3, IgG1
and 1.2B6, IgG1), P-selectin (WAPS12.2, IgG1), VAP-1
(1B2, IgM), VCAM-1 (P8B1, IgG2b) and negative con-
trols 3G6 (IgG1, against chicken T cells), 7C7 (IgM,
against chicken bursal epithelium), kit2c75 (IgG2a, against
chicken c-kit receptor), 3-298 (IgG2b, against chicken CD8
alpha) and MB40.5 (IgG1, against human HLA-ABC)
were used. Peripheral lymph node addressin (PNAd) was
detected with mAb MECA-79 (rat IgM). None of the
mAb stains formalin-fixed, paraffin-embedded sections,
and, therefore, use of frozen sections was mandatory.
Samples of the infarction hearts were processed to paraf-
fin embedded histological specimens in a standard way. The
adjacent tissue samples were immediately embedded in
OCT-compound (Tissue-Tec, Miles Inc., Elkhart, Indi-
ana), frozen in liquid nitrogen, and 5 to 8 mm thick serial
sections were cut. One section stained with the van Gieson
method was used to ascertain sample classification (infarc-
tion, borderzone, remote or reperfused myocardium) and to
localize the inflammatory cell infiltrates. The remaining
sections were stained for the EAMs using indirect immu-
noperoxidase technique as described (11).
Data analysis. All samples were immunostained at least
twice. The interexperimental variation of the staining in-
tensity was controlled by including samples from the infarc-
tion and control hearts in the same experiments and by
including a few given specimens in each staining batch. All
sections were first studied for positivity, and the staining
intensity and the number of positive vessels were recorded in
the whole sections.
In the case of ICAM-1, P-selectin and VAP-1, a
semiquantitative scoring (17) was used. In this system the
number and intensity of positive cardiac vessels was ana-
lyzed in comparison with tonsil vessels used as a positive
control: score 0 was assigned to samples with no positive
blood vessels and score 3 to samples with staining equal to
tonsil. Scores 1 and 2 were adjusted to cover the staining
patterns in between (see also examples in Fig. 1 and 2). In
the case of VAP-1, score 4 was given to the samples that
had more and brighter VAP-positive vessels than in the
tonsil. The samples were analyzed in a blinded manner by
two independent readers (VAP-1 sections twice by three
independent readers). The score for each EAM plotted
Figure 3 is the mean of all estimates given to vasculature in
each sample. The mean (6SEM) of each sample group is
also shown. The data were statistically analyzed with
Kruskal-Wallis test, analysis of variance with Bonferroni
correction and Fisher’s exact test when applicable, and the
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
EAM 5 endothelial adhesion molecule
ICAM 5 intercellular adhesion molecule
mAb 5 monoclonal antibody
PNAd 5 peripheral lymph node addressin
VAP-1 5 vascular adhesion protein-1
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(1 5 yes; 2 5 no)
1 12 h 2
2 3 days 1
3 21/2 days 1
4 24 h 1
5 6 h 2
6 18 h 1
7 3 days 2
8 11 h 1
9 2 days 2
10 7 days 1
AMI 5 acute myocardial infarction.
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statistical significance was set at p , 0.05. In addition,
VAP-1, ICAM-1 and P-selectin positivity of endothelia in
distinct vessel types (capillary, arterial and venous endothe-
lia) were studied in 17 samples.
Functional in vitro tests. The adhesive function of
P-selectin, ICAM-1 and VAP-1 in the heart samples was
evaluated using an in vitro Stamper-Woodruff binding assay
(18). In brief, saturating concentrations of function-
blocking mAbs against VAP-1, P-selectin, ICAM-1, a pool
of isotype-matched negative controls or medium alone were
incubated on the frozen heart sections. Thereafter, granu-
locytes freshly isolated from healthy volunteers (3 3 106
cells in 50 ml RPMI1640 medium containing 10% FCS)
were applied onto each tissue section under constant rota-
tion. After a 30 min rotation at 17°C, the unattached
granulocytes were tilted off, and the sections with adherent
cells were fixed with 1% glutaraldehyde. The granulocytes
attached to the blood vessels of the sections were counted
under a dark field microscope.
Biochemistry of VAP-1. The molecular weights of VAP-1
in remote myocardium, borderzone and infarcted areas and
in the tonsil were compared in immunoblotting using a
previously described method (19). In brief, tissue samples were
lysed, digested with Vibrio cholerae neuraminidase, run under
nonreducing conditions in SDS-PAGE and analyzed using
enhanced chemiluminescence detection system (ECL, Am-
ersham Int.; Buckinghamshire, United Kingdom).
RESULTS
Induction of ICAM-1, P-selectin and VAP-1 in post-
ischemic hearts. Frozen sections from hearts were immu-
nohistochemically stained for nine different EAMs. CD31
(Fig. 1a), ICAM-2 and CD73 were constitutively present in
all samples, and the reactivity was confined to the endothe-
lial cells. E-selectin and the PNAd were completely absent
from the normal hearts in every specimen. Vascular cell
adhesion molecule-1 was weakly positive in the vessels of
12/15 atrial samples but only in 1/8 of normal ventricles
(Fig. 1b). Intercellular adhesion molecule-1 showed mainly
weak staining in normal heart (Fig. 2a and 3a). Faint
P-selectin expression was observed in approximately half of
the atrial samples. In normal ventricles, only one sample out
of eight showed a few P-selectin positive vessels (Fig. 3b).
Vascular adhesion protein-1 was expressed in all specimens
in the small vessels of the myocardium and in the muscular
layer of larger blood vessels. The ventricular expression of
VAP-1 was statistically significantly higher than that in the
atria (Fig. 3c and Table 2). Thus, cardiac vessels in normal
ventricles practically lack E-selectin, P-selectin and
VCAM-1, synthesize low levels of ICAM-1 and ICAM-2
and are clearly positive for VAP-1.
In the reperfused infarction hearts up to 90% of the
leukocytes seen in the myocardium in patients dying within
two days were polymorphonuclears, whereas in the older
lesions the proportion of lymphocytes increased to 75%.
Expression of CD31, CD73, ICAM-2 (Fig. 1c), PNAd and
E-selectin (Fig. 1d) was similar in the AMI ventricles and in
the ventricles of controls. The absence of E-selectin in the
area of infarction was confirmed by another anti-E-selectin
mAb against a different epitope. Only samples from one
AMI heart were weakly positive for VCAM-1. In contrast,
the number of ICAM-1 positive vessels and their intensity
of staining in the AMI ventricles was higher than in the
ventricles of the control hearts (Figs. 2a, b, 3a and Table 2).
There were no statistically significant differences in
ICAM-1 expression between remote, borderzone, infarcted
and reperfused areas or between capillary and venous endo-
thelia. Also P-selectin showed induction during AMI (Fig.
2c to 2e and Fig. 3b). When compared with normal
ventricles, the upregulation of P-selectin was statistically
significant in the remote parts and in the reperfused areas of
the AMI hearts (Fig. 3b and Table 2). The induction of
P-selectin was mainly seen in capillaries or in endothelia of
larger (venous) blood vessels. The slightly lower P-selectin
expression in the infarcted areas was due to less intense
expression of P-selectin in the capillary size blood vessels.
The overall ventricular expression of VAP-1 in capillaries
and venous endothelial cells was not upregulated during
AMI (Fig. 3c and Table 2). However, the intensity of
VAP-1 expression varied in the infarction hearts (Fig. 2, f to
h). Vessels within the areas of dense leukocytic infiltration
often displayed strong VAP-1 expression (Fig. 2h).
Figure 1. Cardiac expression of endothelial adhesion molecules. a) Blood
vessels in normal myocardium are CD31 positive. b) A VCAM-1 positive
blood vessel in normal atrium. c) ICAM-2 positive vessels in infarction
heart. d) Negative staining of infarcted heart with anti-E-selectin mAb
(similar absence of reactivity was also seen with all negative control mAbs,
data not shown). In the inset, E-selectin positive vessels in the tonsil are
shown. Representative vessels are indicated by arrows. Bar shown in (a) is
100 mm. The bar shown in (b) is 50 mm in all other figures. ICAM 5
intercellular adhesion molecule; mAb 5 monoclonal antibody; VCAM 5
vascular cell adhesion molecule-1.
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We did not observe any systematic trend of increasing or
decreasing expression of EAMs when the scores of semi-
quantitatively analyzed molecules were correlated to the
time elapsed from the first symptoms of AMI to the death
of the patients. We conclude that the expression of
ICAM-1 and P-selectin is induced in all parts of the
ischemic heart, and the most intense VAP-1 expression is
found at areas of leukocytic infiltration. In contrast, the
expression of other adhesion molecules does not change
during ischemia-reperfusion.
VAP-1 undergoes structural changes during ischemia.
Since the function of an adhesion molecule is determined
not only by its expression but by appropriate posttransla-
tional modifications as well, we studied VAP-1 as an
example of possible effects of ischemia on the processing of
a protein. In the normal heart (lane 6 in Fig. 4) VAP-1 was
exactly of the same molecular weight as in lymphoid organs
(lane 9 in Fig. 4). In the ischemic heart, the apparent
molecular weight of VAP-1 was slightly higher. The appar-
ent molecular weight of cardiac VAP-1 increased after a
sialidase treatment, the effect being more pronounced in
ischemic than in normal tissue. The electrophoretic mobility
of the sialidase-treated VAP-1 from normal myocardium
remained faster than that from the ischemic sites. The
retardation of electrophoretic mobility after sialidase treat-
ment is consistent with the removal of large numbers of
negatively charged sialic acids from this sialoglycoprotein
molecule. The biochemical analyses were repeated with
three other patients with the same results. These findings
indicate that VAP-1 in all specimens carries these sialic acid
modifications but that the normal heart had a smaller
protein core or differences in other oligosaccharide modifi-
cations.
P-selectin, ICAM-1 and VAP-1 mediate granulocyte
binding to myocardium. Based on the expression data, the
adhesive function of ICAM-1, P-selectin and VAP-1 in
mediating granulocyte binding to the blood vessels of the
infarcted myocardial specimens was studied using an in vitro
adhesion assay. In this binding assay only occasional bound
granulocytes (1–3/100 vessels) were seen in the normal
control heart. In remote areas of the infarcted heart, only a
few adherent leukocytes (1–8/100 vessels) were seen. In
Figure 2. Inducibility and scoring of ICAM-1, P-selectin and VAP-1. a) Moderate (score 2) and b) strong (score 3) ICAM-1 positive samples. c) Weak
(score 1), (d) moderate (score 2) and (e) strong (score 3) P-selectin positive vessels in heart specimens. f) Moderate (score 2), (g) strong (score 3) and (h)
extremely strong (score 4) VAP-1 positive vessels in infarction heart. Representative vessels are indicated by arrows. Bar shown in (a) is 50 mm. ICAM 5
intercellular adhesion molecule; VAP-1 5 vascular adhesion protein-1.
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Figure 3. Intercellular adhesion molecule-1 and P-selectin are induced in ischemic heart, and VAP-1 expression shows ventricular dominance. The
expression of (a) ICAM-1, (b) P-selectin and (c) VAP-1 in normal and infarction heart specimens were scored as described in the Methods section. The
numbers refer to the numbers of individual acute myocardial infarction and control patients. ICAM-1 5 intercellular adhesion molecule-1; VAP-1 5
vascular adhesion protein-1.
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contrast, in the reperfused areas many granulocytes specif-
ically interacted with cardiac vessels (37–208 granulocytes/
100 vessels; Fig. 5a). Granulocyte binding revealed a strong
preference to certain vessels since even in the reperfused
hearts many individual vessels lacked and others were filled
with adherent granulocytes.
Blocking of VAP-1 on the endothelial cells of the
myocardial samples reduced the number of the adherent
granulocytes by 60% when compared with control antibod-
ies (Fig. 5b). Pretreatment of the cardiac sections with
function-blocking mAbs against ICAM-1 and P-selectin
also abrogated about half of the granulocyte binding to
cardiac vessels. When all three adhesion molecules were
rendered nonfunctional at the same time, an additive
inhibitory effect was seen. Thus, in the vessels of infarcted
human heart ICAM-1, P-selectin and VAP-1 mediate
granulocyte binding in vitro.
DISCUSSION
Inducibility and localization of EAM in AMI hearts.
Our material of ischemically injured human myocardium
covers samples in which the tissue has been exposed to
ischemia and reperfusion for various periods of time and,
thus, provides an informative cross-sectional analysis of
EAMs in human AMI. We showed that the normal heart
expresses constitutively several endothelial adhesion mole-
cules (CD31, CD73, ICAM-1, ICAM-2 and VAP-1)
whereas E-selectin and PNAd are not present. Endothelial
adhesion molecules are, in general, equally expressed in the
atrial and ventricular myocardium of the normal heart
(except VAP-1, see following text).
We found ICAM-1 and P-selectin to be upregulated
during AMI. However, the induction was not limited to
areas of ischemia-reperfusion. In fact, increased expression
of ICAM-1 and leukocytic infiltration have also been found
in the nonischemic areas of the infarcted heart (20–22).
There may be several systemic factors contributing to the
induction of these molecules in the whole malfunctioning
heart. Cytokines, including IL-6 and TNF-alpha, which
can be found in blood during hypoxia-ischemia of the heart,
are potent inducers of synthesis of ICAM-1 and P-selectin
(15,23). Hemodynamic changes, known to affect the syn-
thesis of adhesion molecules (24), also take place during
infarction.
P-selectin can be upregulated transiently within minutes
in animal models. In addition to this release from storage
granules, a slower, protein synthesis dependent modulation
of P-selectin is also known (25), which probably accounts
for our findings of P-selectin induction in AMI. E-selectin
is also upregulated in an animal ischemia-reperfusion model
(14) and in the human heart during allograft rejection
(26,27). In contrast, in our series E-selectin was absent from
all human heart specimens. The induction of E-selectin
requires new protein synthesis and is maximal at 2 to 8 h
(28). If E-selectin was expressed in ischemic human myo-
cardium even transiently, it should have been seen in the
patient who died 6 h after the beginning of the symptoms.
Thus, we believe that genuine differences do exist in the
extent and kinetics of P- and E-selectin expression between
the in vivo models and in vivo situations in man, further
emphasizing the importance of human studies.
Figure 4. Molecular weight alterations of VAP-1 in the heart. After
SDS-PAGE and immunoblotting, VAP-1 was immunodetected from
untreated and sialidase treated lysates from normal, reperfused and in-
farcted heart and tonsil as control tissue. To assist size comparisons, all
samples were analyzed in parallel lanes of the same gel, and after the
scanning two horizontal lines were drawn. In the molecular weight (MW)
lane the positions of the markers otherwise not visible in enhanced
chemiluminescense are shown. VAP-1 5 vascular adhesion protein-1.
Table 2. Summary of ICAM-1, P-Selectin and VAP-1 Expression in the Heart
Tissue Sample ICAM-1 P-Selectin VAP-1
Normal atrial 1.3 6 0.16* 0.60 6 0.12 1.6 6 0.15
ventricle 0.86 6 0.26 0.13 6 0.13 2.2 6 0.17
Infarcted remote 1.9 6 0.25 1.4 6 0.30 2.5 6 0.16
borderzone 2.0 6 0.35 1.0 6 0.32 2.5 6 0.14
infarction 1.6 6 0.45 0.57 6 0.30 2.1 6 0.30
reperfused 2.2 6 0.38 1.5 6 0.34 2.5 6 0.28
*The semiquantitative scores of each sample group are given as mean 6 SEM. Sample groups that differ statistically significantly
are connected.
†p , 0.05; ‡p , 0.01.
ICAM-1 5 intercellular adhesion molecule-1; VAP-1 5 vascular adhesion protein-1.
]]]]† ]]‡
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We observed a clear quantitative difference in the expres-
sion of VAP-1 between the atrial and ventricular myocar-
dium. The finding was consistent in samples taken during
surgery and autopsies. In an animal model the expression of
VAP-1 expression in normal tissue is solely intracellular,
whereas in the inflamed tissue luminal VAP-1 expression is
found (29). Since definitive discrimination of VAP-1 reac-
tivity in cytoplasmic granules (30) and at luminal (function-
al) position on the endothelial surface is not possible with
immunohistochemistry in postmortem specimens, it is pos-
sible that induction of functionally relevant expression of
VAP-1 in ischemically injured tissue is more selective than
observed in this study. Also, in AMI material, prominent
leukocyte infiltration was often observed around brightly
VAP-1 positive vessels, suggesting that in these areas
VAP-1 expression may be functionally more significant
than appears from the pooled data of the whole section (Fig.
3c). The unique observation of the structural changes in
VAP-1 during AMI can be considered as an example of an
additional control mechanism to regulate the function of the
EAMs. It may apply to other adhesion molecules as well.
Functional relevance and clinical implications of EAM
in AMI. In animal models of myocardial damage, anti-P-
selectin antibodies (4) and anti-ICAM-1 antibodies (5,7)
have reduced the amount of tissue necrosis by 20% to 50%.
The expression pattern of VAP-1, ICAM-1 and P-selectin
together with the reduction of leukocyte interaction with
vessels in infarcted hearts by 37% to 78% after pretreatment
with function blocking antibodies strongly suggest that
these molecules mediate leukocyte immigration into isch-
emically injured heart in man. The ex vivo binding assay
used reflects the actual migration patterns in vivo (31).
Notably, granulocyte binding to inflamed tonsils is only
marginally affected by anti-VAP-1 mAbs (11), and, hence,
the VAP-1 dependence of binding of polymorphonuclear
cells to cardiac vessels is a notable extension in the biological
role of this molecule.
Conclusions. Our results show that the dynamic events in
human AMI result in altered expression of functionally
active endothelial molecules mediating leukocyte-
endothelium interactions. Our results indicate that potential
target molecules for studies to prevent leukocyte mediated
cardiomyocyte damage and endothelial dysfunction in man
are found among ICAM-1, P-selectin and VAP-1.
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Figure 5. Intercellular adhesion molecule-1, P-selectin and VAP-1 mediate granulocyte adhesion to vessels in infarcted heart. a) In this dark field picture
two cardiac vessels (dashed lines) are shown, one with seven bound granulocytes and the other supporting the binding of two granulocytes (arrows). b)
Anti-VAP-1, P-selectin and anti-ICAM-antibodies separately or in combination decrease the number of granulocytes adhering to myocardial blood vessels
when compared with the specimens treated with nonbinding (set as 100%) control antibodies or without any antibodies (2). ICAM 5 intercellular adhesion
molecule; VAP-1 5 vascular adhesion protein-1.
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